Re-vascularisation in human ovarian tissue after conventional freezing or vitrification and xenotransplantation

Systematic Review of Available Guidelines on Fertility Preservation of Young Patients with Breast Cancer

“…Usage of less gonadotoxic regimens for adjuvant or neoadjuvant chemotherapy is a good choice and may be considered in YBCP with favorable tumors characteristic (Lobo, 2005;Kim et al, 2011). When cryopreservation of embryos or oocytes is not possible, ovarian tissue cryopreservation can be considered without a delay in cancer treatment (Oktay et al, 2003;2005;Dolmans et al, 2010;Rahimi et al, 2010;Kim et al, 2011;ISFP Practice Committee et al, 2012;Husseinzadeh, 2013). Although many scientific or technical aspects of fertility preservation options are presented in current recommendations and guidelines, this matter raises several important ethical and legal issues that should be adequately addressed to young patients or parents before such techniques are used.…”

“…Ovarian freezing as the emerging discipline of assisted reproductive technologies is progressively attracting interest to preserve fertility for young cancer patients. Fertility preservation options have also been used for other diseases such as lupus, glomerulonephritis, myelodysplasia, and premature ovarian failure as well as in women who wish to preserve their ovarian function for future reproductive potential and delayed childbearing age (Posada et al, 2001;Imhof et al, 2004;Demeestere et al, 2007;Maltaris et al, 2007;Isachenko et al, 2007;Ajala et al, 2010;Rahimi et al, 2010;Dolmans et al, 2010;Michaeli et al, 2012;Husseinzadeh, 2013). Despite rapid progress in cryopreservation technology and existing other resources and infrastructure, fertility preservation for young breast cancer patients is in its early stage with many challenges (Posada et al, 2001;Imhof et al, 2004; National Collaborating Center for Women's and Children's Health (UK), 2004; Sonmezer and Oktay, 2004;Lee et al, 2006;Demeestere et al, 2007;Isachenko et al, 2007;Maltaris et al, 2007;Ajala et al, 2010;Dolmans et al, 2010;Ewertz and Jensen, 2010;Rahimi et al, 2010;Christinat and Pagani, 2012;Klemp and Kim, 2012;King et al, 2012;Michaeli et al, 2012;Klemp and Kim, 2012;King et al, 2012;Fields et al, 2013;Husseinzadeh, 2013;Husseinzadeh and Husseinzadeh, 2013;Leclere et al, 2013;Loren et al, 2013;Ronn and Holzer, 2013).…”

Ewe Ovarian Tissue Vitrification: A Model for the Study of Fertility Preservation in Women

“…Rahimi et al (2004) observed no increase in necrotic area proportion in the human vitrified-thawed ovarian tissue after 42 days of subcutaneous xenotransplantation in severe combined immunodeficiency (SCID) mice compared to fresh or slow human cryopreserved ovarian tissue. In contrast, the same team later reported that xenografts of vitrified-thawed human ovarian tissue in SCID mice after 30 days had a significantly greater amount of apoptotic cells, when compared to slow frozen (Rahimi et al, 2009).…”

“…After human ovarian tissues were vitrified, thawed, and xenotransplanted for 30 days in SCID mice, the tissues were observed to have vascularization similar to tissues undergoing a similar process, but had been previously frozen (Rahimi et al, 2010). Amorim et al (2012) observed a lower percentage of DNA damage in follicles within vitrified-thawed human ovarian tissue after 7 days of xenotransplantation in SCID mice.…”

“…Ovary vitrification in women, combined with xenotransplantation is an ample field for research, but few studies have investigated xenografting after warmed, post-vitrified human ovarian tissue (Rahimi et al, 2004;Rahimi et al, 2009;Rahimi et al, 2010;Amorim et al, 2012). Rahimi et al (2004) observed no increase in necrotic area proportion in the human vitrified-thawed ovarian tissue after 42 days of subcutaneous xenotransplantation in severe combined immunodeficiency (SCID) mice compared to fresh or slow human cryopreserved ovarian tissue.…”